Response rates--an evolution.
The documented frequency of response of cancers to common chemotherapy agents and combinations appears to have decreased over the decades. Multiple reasons exist for this decline including: changes in eligibility and evaluability criteria; changes in the type of patients entered onto trial; and, altered criteria for response and methods for response assessment. The disinclination to publish negative results also permits a bias in a favor of overestimating a drug's efficacy. Circumspection now is advised in assessing data from older trials.
Wayne State University, Division of Hematology and Oncology, Detroit, MI 48201.
E
E
Poplin
L
L
Baker
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015986:Confounding Factors, Epidemiologic; D004351:Drug Resistance; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012107:Research Design; D016896:Treatment Outcome
D000970:Antineoplastic Agents